Please enable JavaScript.
Coggle requires JavaScript to display documents.
Ulcerative Colitis, Signs & Symptoms, ACG (2025): Evidence-based…
Ulcerative Colitis
Clinical Reasoning
Bloody diarrhea: Mucosal ulceration and inflammation cause rectal bleeding and frequent loose stools.
Abdominal pain and urgency: Colonic inflammation increases bowel motility and causes cramping, urgency, and tenesmus.
Fatigue and anemia: Chronic intestinal blood loss and inflammation may contribute to iron deficiency anemia and fatigue.
Dehydration and electrolyte imbalances: Frequent diarrhea increases fluid and electrolyte losses.
Disease severity: Evaluate stool frequency, bleeding, vital signs, inflammatory markers, hemoglobin, and endoscopic findings to determine severity.
Complications: Severe inflammation may cause acute severe colitis, toxic megacolon, perforation, or significant hemorrhage. Long-standing extensive colitis increases colorectal cancer risk.
APRN decision-making: Assess for disease flares, exclude infectious causes such as Clostridioides difficile, monitor complications, and coordinate treatment or gastroenterology referral based on disease severity.
Patho
Genetic and Environmental Factors: Genetic susceptibility, alterations in gut microbiota, and environmental exposures contribute to intestinal inflammation.
Mucosal Involvement: Inflammation primarily affects the mucosa and may extend into the superficial submucosa, unlike Crohn's disease, which involves transmural inflammation.
Continuous Inflammation: Inflammation typically begins in the rectum and extends proximally through the colon in a continuous pattern.
Epithelial Barrier Disruption: Damage to the intestinal epithelial barrier contributes to increased permeability, mucosal ulceration, bleeding, and mucus production.
Crypt Abscesses: Neutrophils accumulate within intestinal crypts, contributing to mucosal injury and serving as a characteristic histologic finding of active inflammation. Crypt abscesses are characteristic of active UC but are not exclusive to UC, so they should not be presented as diagnostic on their own.
Chronic Immune-Mediated Inflammation: Dysregulated intestinal immune responses cause chronic inflammation of the colon and rectum.
Assessment
History: bleeding, stool frequency and characteristics, urgency
Medication, allergies, medical history, and family history
Vitals, weight, and hydration status
Abdominal exam, palpation, assessing overall severity and patient stability
Nutrition status, fluid intake
Influential Factors
Genetic
8–14% of patients have a family history of IBD
First-degree relatives have about 4-fold to 8-fold higher risk.
genotyping has little predictive value and is currently of limited clinical use.
Environmental
Factors that decrease risk: current smokers, appendectomy, breastfeeding, tea consumption
Factors that increase risk: former smokers, hx of gastroenteritis (Salmonella, Shigella, Campylobacter), use of OCPs/HRT/NSAIDs, vit D deficiency, urban living, consuming soft drinks
Psychosocial
Childhood physical or sexual abuse, short sleep, and depression have been associated with higher odds of UC or IBD
Newer prospective data link high perceived stress to a higher risk of clinical flares
Depression affects about 15–40% of patients with UC, and rates rise with active disease.
Cultural
Ethnicity (rates higher in Jewish populations)
Percieved stigma
Pharmacological/ Treatment Planning
Mild to moderate UC
Mesalamine (5-ASA) to reduce inflammation and help maintain remission
Orally or Rectal
Be sure to monitor renal function with mesalamine; assess infection risk
Severe UC
Infliximab, Vedolizumab, and Ustekinumab
Corticosteroids
Prednisone or budesonide or systemic corticosteroids may be used to induce remission
Not recommended for long term maintenance
Patient Education and Health Promotion
Diet
Identify individual food triggers, maintain hydration, and work with dietitian
Health promotion
Review vaccinations, nutrition, colorectal cancer surveillance, and mental health
Medication adherence
Continue prescribed maintenance treatment even when symptoms improve
Information Technologies
Telehealth
Allows APRNs to assess symptoms, monitor medication adherence, and provide follow-up care for patients with UC
Mobile Health Applications
Help patients track bowel movements, rectal bleeding, dietary triggers, medications, and possible flare symptoms
Electronic Health Records (EHR)
Track UC symptoms, lab results, medications, and treatment response
Diagnosis & Testing
Stool Studies: exclude infection/ C. difficile
Fecal Calprotectin: intestinal inflammation
GI: colonoscopy with biopsies
CBC, CMP, Albumin, CRP, Vitamin D, ESR
Referrrals/Collaboration
Colorectal Surgeon: Referral for refractory disease, colorectal dysplasia or cancer, or severe complications.
Registered Dietitian: Nutritional counseling, dietary modifications, and management of nutritional deficiencies.
Gastroenterologist: Referral for colonoscopy, disease management, advanced therapies, and persistent symptoms.
Community and Patient Support Resources
Crohn's & Colitis Foundation: Provides educational materials, support groups, and disease management resources.
Mental Health Services: Counseling and psychological support for anxiety, depression, and chronic disease management.
APRN Scope of Practice
Assessment: Evaluate symptoms, risk factors, nutritional status, and disease severity.
Diagnosis: Order and interpret laboratory and stool studies; coordinate colonoscopy with biopsy.
Management: Manage appropriate medications, monitor adverse effects, and coordinate specialty care.
Prevention: Promote vaccinations, nutritional health, medication adherence, and colorectal cancer surveillance.
Follow-Up: Monitor symptoms, inflammatory markers, and treatment response to maintain remission.
Risk Factors
Family history/genetics: Including family hx of IBD
Western diet: alternations in the gut may contribute to disease development
Early-life antibiotics
NSAID use
Urban living
Protective: smoking
Prevelance
Prevalence: Approximately 3.1 million U.S. adults (1.2%) reported a history of ulcerative colitis (Dahlhamer & Terlizzi, 2026).
Screening Prevention
Primary Prevention: No proven way to prevent UC. Healthy eating and avoiding unnecessary antibiotic use may help support gut health.
Early Detection: Evaluate patients with persistent bloody diarrhea, abdominal pain, or rectal urgency.
Colorectal Cancer Screening: Surveillance colonoscopy typically begins 8 years after symptom onset, depending on disease extent and risk factors.
Tertiary Prevention: Maintenance medications, such as 5-ASA and biologics, help control inflammation, prevent flares, and reduce complications.
Morbidity & Mortality
Morbidity
Chronic disease with recurring flares that often requires lifelong treatment.
Extensive colitis increases the risk of hospitalization and colectomy.
Complications include anemia, malnutrition, and colorectal cancer.
Mortality
Severe disease and complications increase the risk of death.
Long-standing, extensive UC increases the risk of death from colorectal cancer.
Signs & Symptoms
Abdominal cramps, fatigue
Weight loss or anemia
Bloody diarrhea, mucous in stool, urgency
Possible joint, skin, or eye symptoms
ACG (2025): Evidence-based guidelines for UC diagnosis, treatment, monitoring, and maintenance of remission.
&
AGA (2023): Recommends using fecal calprotectin and CRP alongside clinical symptoms to evaluate disease activity and treatment response.
Clinical Guidelines